Once we determine which patients should receive further treatment based on the probability of colon cancer relapse, the next step is to determine what the best treatment option is. Auspex is the first in the world to offer chemotherapy efficacy prediction based on patient’s gene data from tumor biopsy.
Similar to the recurrence test, based on the results from the chemotherapy efficacy prediction tests oncologists and patients can better determine what chemotherapy options are the most effective and save the time and costs receiving ineffective (most time even harmful) chemo treatment. We currently have the ability to predict the efficacy of two most common colorectal cancer chemotherapy treatment methods: 5-FU and FOLFOX.
Combining both the recurrence prediction and the chemotherapy efficacy prediction diagnostics, Auspex will be able offer a complete suite of services to help oncologists to better personalize treatment for their patients.